Challenging diagnosis of a rare disease: hypophosphatemic osteomalacia – case report and literature review
DOI:
https://doi.org/10.12775/JEHS.2024.72.51116Keywords
osteomalacia, tumor-induced osteomalacia, hypophosphatemia, fibroblast growth factor-23, vitamin D, calcium-phosphate managementAbstract
Hypophosphatemic osteomalacia is a rare condition caused by different causes, all resulting in disturbances of calcium-phosphate management. One of the most common causes among adults is tumor-induced osteomalacia, which is characterized by increased secretion of fibroblast growth factor-23. Its symptoms are vague, tests necessary for diagnosis are not commonly used by clinicians and some of them are only available in highly specialized centers. Due to these reasons, patients often are misdiagnosed for more common conditions and are left without proper treatment for many years. We present a case of a patient suffering from multiple fractures, diffuse bone pain, and muscle weakness, who was previously misdiagnosed for osteoporosis, primary and secondary hyperparathyroidism. We discuss the pathophysiology of tumor-induced osteomalacia, diagnostic path, differential diagnosis, available forms of treatment and possible complications.
References
Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024;38(2):101851. doi:10.1016/J.BEEM.2023.101851
Rendina D, Abate V, Cacace G, et al. Tumor-induced Osteomalacia: A Systematic Review and Individual Patient’s Data Analysis. J Clin Endocrinol Metab. 2022;107(8):e3428-e3436. doi:10.1210/clinem/dgac253
Portales-Castillo I, Rieg T, Khalid SB, Nigwekar SU, Neyra JA. Physiopathology of Phosphate Disorders. Advances in Kidney Disease and Health. 2023;30(2):177-188. doi:10.1053/J.AKDH.2022.12.011
Yin Z, Du J, Yu F, Xia W. Tumor-induced osteomalacia. Osteoporos Sarcopenia. 2018;4(4):119-127. doi:10.1016/J.AFOS.2018.12.001
Kim KJ, Song JE, Kim JH, et al. Elevated morbidity and mortality in patients with chronic idiopathic hypophosphatemia: a nationwide cohort study. Front Endocrinol (Lausanne). 2023;14. doi:10.3389/fendo.2023.1229750
Aligail K, Dave JA, Ross IL. Tumor-induced osteomalacia: a case report. J Med Case Rep. 2022;16(1). doi:10.1186/s13256-021-03220-7
Jadhav SS, Shah R, Patil V. Tumor-induced osteomalacia: An overview. Best Pract Res Clin Endocrinol Metab. 2024;38(2):101834. doi:10.1016/J.BEEM.2023.101834
Bosman A, Palermo A, Vanderhulst J, et al. Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases. Calcif Tissue Int. 2022;111(4):367-379. doi:10.1007/s00223-022-01005-8
Cundy T, Que L, Hassan IM, Hughes L. Bisphosphonate‐Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus. 2020;4(8). doi:10.1002/jbm4.10374
Lee GJ, Marks J. Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond? Pediatric Nephrology. 2015;30(3):363-371. doi:10.1007/s00467-014-2759-x
Sabbagh Y, Giral H, Caldas Y, Levi M, Schiavi SC. Intestinal Phosphate Transport. Adv Chronic Kidney Dis. 2011;18(2):85-90. doi:10.1053/j.ackd.2010.11.004
Yee J, Rosenbaum D, Jacobs JW, Sprague SM. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications. Am J Nephrol. 2021;52(7):522-530. doi:10.1159/000518110
Fukumoto S. The role of bone in phosphate metabolism. Mol Cell Endocrinol. 2009;310(1-2):63-70. doi:10.1016/j.mce.2008.08.031
Thomas L, Dominguez Rieg JA, Rieg T. Npt2a as a target for treating hyperphosphatemia. Biochem Soc Trans. 2022;50(1):439-446. doi:10.1042/BST20211005
Bergwitz C, Jüppner H. Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23. Annu Rev Med. 2010;61(1):91-104. doi:10.1146/annurev.med.051308.111339
Kolek OI, Hines ER, Jones MD, et al. 1α,25-Dihydroxyvitamin D 3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2005;289(6):G1036-G1042. doi:10.1152/ajpgi.00243.2005
Goltzman D, Mannstadt M, Marcocci C. Physiology of the Calcium-Parathyroid Hormone-Vitamin D Axis. In: ; 2018:1-13. doi:10.1159/000486060
Aljuraibah F, Bacchetta J, Brandi ML, et al. An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia. Journal of Bone and Mineral Research. 2022;37(1):12-20. doi:10.1002/jbmr.4486
Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis. Journal of Bone and Mineral Research. 2004;19(3):429-435. doi:10.1359/JBMR.0301264
Saponaro F, Saba A, Zucchi R. An Update on Vitamin D Metabolism. Int J Mol Sci. 2020;21(18):6573. doi:10.3390/ijms21186573
Jan de Beur SM, Minisola S, Xia W bo, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. 2023;293(3):309-328. doi:10.1111/joim.13593
Hori M, Shimizu Y, Fukumoto S. Minireview: Fibroblast Growth Factor 23 in Phosphate Homeostasis and Bone Metabolism. Endocrinology. 2011;152(1):4-10. doi:10.1210/en.2010-0800
Fukumoto S, Hasegawa Y. Special Issue: “X-Linked Hypophosphatemia.” Endocrines. 2023;4(4):720-721. doi:10.3390/endocrines4040052
Gupta A, Dwivedi A, Patel P, Gupta S. Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: Case report and literature review. Indian Journal of Radiology and Imaging. 2015;25(1):63-66. doi:10.4103/0971-3026.150155
Obo T, Koriyama N, Tokito A, Ogiso K, Nishio Y. Neurofibromatosis type 1 associated with hypophosphatemic osteomalacia due to hypersecretion of fibroblast growth factor 23: A case report. J Med Case Rep. 2020;14(1). doi:10.1186/s13256-020-02381-1
Kancherla K, Constantin H, Kanawati A, Graham E. Iron-induced Hypophosphatemic Osteomalacia-An Atypical Case of Bilateral Femoral Stress Fractures. J Am Acad Orthop Surg Glob Res Rev. 2023;7(5). doi:10.5435/JAAOSGlobal-D-22-00155
Samões B, Silva B, Martins A, et al. Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report. Joint Bone Spine. 2023;90(5):105586. doi:10.1016/J.JBSPIN.2023.105586
Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. Journal of Bone and Mineral Research. 2022;37(6):1188-1199. doi:10.1002/jbmr.4558
He H, Zhang YJ. Multiple-level spinal fractures due to adefovir-induced Fanconi syndrome and hypophosphatemic osteomalacia: A case report. Asian J Surg. 2023;46(4):1712-1713. doi:10.1016/J.ASJSUR.2022.09.140
Palermo A, Strollo R, Papalia R, et al. Severe hypophosphatemic osteomalacia secondary to fanconi syndrome due to adefovir: A case report. Endocrine Practice. 2014;20(12):e246-e249. doi:10.4158/EP14251.CR
Wang M, Cao X, Cao B. Hypophosphatemic vitamin D-resistant osteomalacia: A case report. Exp Ther Med. 2013;6(3):791-795. doi:10.3892/etm.2013.1209
Hawke K, Croft A, Lazarus S. Tumor-Induced Osteomalacia in a Patient with Crohn’s Disease: A Case Report and Approach to Investigating Hypophosphatemia. Case Rep Gastroenterol. Published online 2024:81-89. doi:10.1159/000536136
Li X, Cheng D, Sun Z, Jiao Q, Wang C, Fan Y. An Unusual Case of Bone Pain, Hypophosphatemia, and a Gastric Mass: A Quiz. American Journal of Kidney Diseases. 2024;83(3):A16-A20. doi:10.1053/j.ajkd.2023.09.013
Ikegawa K, Hasegawa Y. Presentation and Diagnosis of Pediatric X-Linked Hypophosphatemia. Endocrines. 2023;4(1):128-137. doi:10.3390/endocrines4010012
Fukumoto S. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol. 2021;66(2):R57-R65. doi:10.1530/JME-20-0089
Jiang Y, Li X, Huo L, et al. Consensus on clinical management of tumor-induced osteomalacia. Chin Med J (Engl). 2021;134(11):1264-1266. doi:10.1097/CM9.0000000000001448
Takeuchi Y, Suzuki H, Ogura S, et al. Venous Sampling for Fibroblast Growth Factor-23 Confirms Preoperative Diagnosis of Tumor-Induced Osteomalacia. J Clin Endocrinol Metab. 2004;89(8):3979-3982. doi:10.1210/jc.2004-0406
Minisola S, Fukumoto S, Xia W, et al. Tumor-induced Osteomalacia: A Comprehensive Review. Endocr Rev. 2023;44(2):323-353. doi:10.1210/endrev/bnac026
Paramba F, Silas M, Masoodi N, Benjamin S, Palaki JA. Hypophosphatemic Osteomalacia in a Young Adult. Cureus. Published online March 4, 2021. doi:10.7759/cureus.13697
Brunelli SM, Goldfarb S. Hypophosphatemia: Clinical consequences and management. Journal of the American Society of Nephrology. 2007;18(7):1999-2003. doi:10.1681/ASN.2007020143
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. Journal of Bone and Mineral Research. 2011;26(7):1381-1388. doi:10.1002/jbmr.340
Spaleniak S, Kade G, Kidziński R, Mazurek A, Lubas A, Niemczyk S. Tumor-induced hypophosphatemic osteomalacia as a rare cause of bone pain. Pol Arch Intern Med. 2018;128(3):189-191. doi:10.20452/pamw.4234
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Agnieszka Nowak, Alicja Partyka, Magdalena Pach, Justyna Dobrzańska, Mariola Dziedzic, Aneta Michalczewska, Agnieszka Fugas, Natalia Wierzejska, Zuzanna Chmielowiec, Karolina Smykiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 246
Number of citations: 0